Sndl Inc. (SNDL) intrinsic value & 10-year financials

Sndl Inc. (SNDL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 111.0% a year to CAD 712.2M, with an average return on invested capital of -92.5%.

Graham intrinsic value
—
Revenue (FY2022)
CAD 712.2M
Revenue growth (6-yr CAGR)
111.0%
ROIC (10-yr avg)
-92.5%
Free cash flow (FY2022)
-CAD 17.4M

SNDL 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2022 CAD 712.2M -CAD 372.4M — -CAD 17.4M -48.8% —
FY2021 CAD 56.1M -CAD 230.2M — -CAD 159.2M -235.4% —
FY2020 CAD 60.9M -CAD 239.9M — -CAD 60.5M -304.4% —
FY2019 CAD 75.9M -CAD 271.6M — -CAD 250.9M -209.9% -85.4%
FY2018 — -CAD 13.0M — -CAD 12.8M — -99.7%
FY2017 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in CAD.

Executive summary

SNDL Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

SNDL Inc. has historically struggled to out-earn its cost of capital, averaging just -92.5% ROIC.

SNDL Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, SNDL Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-53814.76 per share.

SNDL stock: frequently asked questions

Does Sndl Inc. generate free cash flow?

Sndl Inc. generated -CAD 17.4M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2022. Free cash flow was positive in 0 of the last 5 reported years.

What is SNDL's return on invested capital?

Average ROIC over the last 6 fiscal years was -92.5%, and average return on equity was -97.8%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this SNDL data come from?

From Sndl Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Mar 21, 2024. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar medicinal chemicals & botanical products stocks